Abstract
A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr-D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.
Keywords: Antibiotics, biofilm, cyclic lipopeptides, eradication, fusaricidins/LI-Fs, MRSA, porcine model, wound.
Protein & Peptide Letters
Title:In Vitro and In Vivo Activities of Novel Cyclic Lipopeptides Against Staphylococcal Biofilms
Volume: 21 Issue: 4
Author(s): Nina Bionda, Irena Pastar, Stephen C. Davis and Predrag Cudic
Affiliation:
Keywords: Antibiotics, biofilm, cyclic lipopeptides, eradication, fusaricidins/LI-Fs, MRSA, porcine model, wound.
Abstract: A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr-D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.
Export Options
About this article
Cite this article as:
Bionda Nina, Pastar Irena, Davis C. Stephen and Cudic Predrag, In Vitro and In Vivo Activities of Novel Cyclic Lipopeptides Against Staphylococcal Biofilms, Protein & Peptide Letters 2014; 21 (4) . https://dx.doi.org/10.2174/09298665113206660101
DOI https://dx.doi.org/10.2174/09298665113206660101 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design Preparation and Characterization of Chitosan-Based Spray-Dried Microparticles for the Delivery of Clindamycin Phosphate to Periodontal Pockets
Current Drug Delivery A Review of the Carbapenems in Clinical Use and Clinical Trials
Recent Patents on Anti-Infective Drug Discovery Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Characterization of a Bacteriophage-Derived Murein Peptidase for Elimination of Antibiotic-Resistant Staphylococcus aureus
Current Protein & Peptide Science Recent Advances in Analytical Techniques used for the Determination of Fluoroquinolones in Pharmaceuticals and Samples of Biological Origin - A Review Article
Current Pharmaceutical Analysis In silico Analysis of Toxins of Staphylococcus aureus for Validating Putative Drug Targets
Infectious Disorders - Drug Targets Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Development and Validation of a UV-Spectrophotometric Method for Determination of Flucloxacillin Sodium in Capsules
Current Pharmaceutical Analysis Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses Calcific Aortic Stenosis: Molecular and Cellular Mechanisms, Medical Treatment Alternatives
Current Cardiology Reviews Evaluation and Management of Asymptomatic Bradyarrhythmias
Current Cardiology Reviews Evolution and Analysis of Heterogeneity in the Clinical Expression of Aortic Diseases Similar to Marfan’s Syndrome: Challenge and Art in Clinical Diagnosis
Current Rheumatology Reviews Oral Hygiene and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Linezolid Induced Skin Reactions in a Multi Drug Resistant Infective Endocarditis Patient: A Rare Case
Current Drug Safety The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Concurrent Methicillin-Resistant <i>Staphylococcus aureus Septicemia</i> and Thyroid Abscess in a Young Male with Dengue
Infectious Disorders - Drug Targets Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design